CompletedNot Applicable

Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

China636 participantsStarted 2018-01-02

Plain-language summary

This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy Exclusion Criteria: * EGFR/ALK/ROS1 driver gene mutation * Chemotherapy only * Concurrent radio-chemotherapy * Surgery * Single-agent immunotherapy * No treatment information available

What they're measuring

PFS

Timeframe: January 2018 to June 2021

Trial details

NCT IDNCT05205226

SponsorHunan Province Tumor Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-05

View on ClinicalTrials.gov More Non Small Cell Lung Cancer trials